South African Parents' and Grandparents' Perspectives on the Acceptability of Implant Delivery of Treatment to Young Children with HIV.
Caregivers
HIV treatment
Implants
Pediatric populations
Qualitative end-user research
Journal
AIDS and behavior
ISSN: 1573-3254
Titre abrégé: AIDS Behav
Pays: United States
ID NLM: 9712133
Informations de publication
Date de publication:
28 Oct 2024
28 Oct 2024
Historique:
accepted:
16
09
2024
medline:
28
10
2024
pubmed:
28
10
2024
entrez:
28
10
2024
Statut:
aheadofprint
Résumé
Children living with HIV (CLWH) face unique challenges with adherence to antiretroviral therapy. In South Africa, just over a third of children receiving antiretroviral therapy are virally suppressed. Long-acting, subcutaneous implants may improve outcomes in CLWH compared to current daily oral dosing regimens. Qualitative in-depth interviews and focus group discussions (FGD) were conducted with 50 caregivers of CLHW in Johannesburg, South Africa. Interviews and FGDs were audio-recorded and transcribed. Data were coded and analyzed using Dedoose v9 software and a thematic approach. Caregivers had generally positive impressions of the pediatric HIV treatment implant. They emphasized the advantages of a long-acting and discreet treatment option for CLWH. Cited advantages were perceived to have widespread impact on CLWH, their caregivers, and other social dynamics. Caregivers raised some concerns or uncertainties about the potential efficacy, side effects and safety of the implant. Future clinical testing and outreach efforts may address such concerns and mitigate potential misinformation about implants. This study indicates the need to develop long-acting, discreet, safe, and efficacious HIV treatment options for young children.
Identifiants
pubmed: 39465464
doi: 10.1007/s10461-024-04515-8
pii: 10.1007/s10461-024-04515-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
UNAIDS. 2023 estimates. Global HIV & AIDS statistics - fact sheet 2023.
HIV/AIDS JUNPo. UNAIDS Data 2023. Switzerland: Geneva; 2023.
Saitoh A, Foca M, Viani RM, et al. Clinical outcomes after an unstructured treatment interruption in children and adolescents with perinatally acquired HIV infection. Pediatr Mar. 2008;121(3):e513–521.
doi: 10.1542/peds.2007-1086
Schlatter AF, Deathe AR, Vreeman RC. The need for Pediatric formulations to treat children with HIV. AIDS Res Treat. 2016;2016:1654938.
pubmed: 27413548
pmcid: 4927993
Nemathaga L, Mafune R, Lebese R. Challenges faced by caregivers of children on antiretroviral therapy at Mutale Municipality selected healthcare facilities, Vhembe District, Limpopo Province. Curationis. 2017;40(1):1–9.
(NIAID) NIoAaID. HIV Treatment in Infants and Children. 2019; https://www.niaid.nih.gov/diseases-conditions/hiv-treatment-children
Study of Oral and Long-Acting Injectable Cabotegravir. And Rilpivirine in Virologically Suppressed Children Living with HIV-1, Two to Less Than 12 Years of Age. 2022; https://classic.clinicaltrials.gov/show/NCT05660980
Moffatt K, Tekko IA, Vora L, et al. Development and evaluation of dissolving microarray patches for co-administered and repeated intradermal delivery of long-acting Rilpivirine and Cabotegravir Nanosuspensions for Paediatric HIV antiretroviral therapy. Pharm Res Jul. 2023;40(7):1673–96.
Abrams EJ, Capparelli E, Ruel T, Mirochnick M. Potential of long-acting products to transform the Treatment and Prevention of Human Immunodeficiency Virus (HIV) in infants, children, and adolescents. Clin Infect Dis. 2022;75(Supplement4):S562–70.
doi: 10.1093/cid/ciac754
pubmed: 36410381
pmcid: 10200315
Lochmiller CR. Conducting Thematic Analysis with Qualitative Data. The Qualitative Report. 2021.
Hawley I, Scorgie F, Pahad S et al. Healthcare providers’ views on the acceptability of implants for HIV treatment in young children in Johannesburg, South Africa. Paper presented at: International Association of Providers of AIDS Care Adherence 20212021; Orlando, FL, United States.
Scorgie F, Hawley I, Fairlie L, et al. Acceptability of implants for HIV Treatment in Young children: perspectives of Health Care providers in Johannesburg, South Africa. AIDS Patient care STDs Oct. 2022;36(10):389–95.
doi: 10.1089/apc.2022.0087
Krogstad EA, Atujuna M, Montgomery ET, et al. Perspectives of South African youth in the development of an implant for HIV prevention. J Int AIDS Soc. 2018;21(8):e25170.
doi: 10.1002/jia2.25170
pubmed: 30152004
pmcid: 6111144
Krogstad EA, Montgomery ET, Atujuna M, et al. Design of an Implant for Long-Acting HIV Pre-exposure Prophylaxis: Input from South African Health Care Providers. AIDS Patient care STDs Apr. 2019;33(4):157–66.
doi: 10.1089/apc.2018.0177
Brown MS, Hanif H, Little KM, et al. End-user research in support of long-acting systemic antiretroviral delivery systems: insights from qualitative research with providers and target users in South Africa. BMC Infect Dis. 2022;2022/12/08(1):919.
doi: 10.1186/s12879-022-07907-0
Browne E, Manenzhe K, Makoni W et al. Incorporating End-Users’ Voices into the Development of an Implant for HIV Prevention: A Discrete Choice Experiment in South Africa and Zimbabwe2022.
Schieffer RJ, Bryndza Tfaily E, D’Aquila R, et al. Conjoint Analysis of user acceptability of sustained long-acting Pre-exposure Prophylaxis for HIV. AIDS Res Hum Retroviruses Apr. 2022;38(4):336–45.
doi: 10.1089/aid.2021.0075
Nkomo S, Makoni W, Shapley-Quinn MK, et al. Prospective acceptability of a multipurpose technology (MPT) implant in preclinical development to prevent HIV and unplanned pregnancy: qualitative insights from women end users and health care providers in South Africa and Zimbabwe. PLoS ONE. 2023;18(5):e0285711.
doi: 10.1371/journal.pone.0285711
pubmed: 37195918
pmcid: 10191314
Montgomery ET, Hawley I, Fairlie L et al. Acceptability of the Dapivirine Vaginal Ring and oral Truvada among African users in late-stage of pregnancy. AIDS Behav 2024;28(3):963–973. https://doi.org/10.1007/s10461-023-04203-z .
Stoner MCD, Hawley I, Mathebula F et al. Acceptability and Use of the Dapivirine Vaginal Ring and Daily Oral Pre-exposure Prophylaxis (PrEP) During Breastfeeding in South Africa, Malawi, Zimbabwe, and Uganda. AIDS and Behavior. 2023/12/01 2023;27(12):4114–4123.